Clinical Stage Drug Discovery Based on Our Proprietary Platform Technology

SMNH: Delivering Novel Chemistry Solutions for Today's Diseases

SB 9200: A Potential Breakthrough Drug for HCV

Latest News

Publications

  • Poonam Advani, Blessy Joseph, Premlata Ambre, Raghuvir Pissurlenkar, Vijay Khedkar, Krishna Iyer, Satish Gabhe, Radhakrishnan P. Iyer & Evans Coutinho (2015): In silico optimization of pharmacokinetic properties and receptor binding affinity simultaneously: a ‘parallel progression approach to drug design’ applied to β-blockers, Journal of Biomolecular Structure and Dynamics, May 20, 2015, DOI: 10.1080/07391102.2015.1033646  read
  • Coughlin, J. E., Pandey R. K., Padmanabhan, S. O’Loughlin, K.,Green,C. E., Mirsalis,J., Iyer, R. P. Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-HBV dinucleoside phosphorothioate. Drug Disposition and Metabolism (The American Society for Pharmacology and Experimental Therapeutics). 2012, 40, 970-981.
  • Ambre, P K., Pissurlenkar, R. R. S., Coutinho, E. C., Iyer, R. P. A unified model for Checkpoint-Kinase-1 inhibitors based on Docking, 3D-QSAR, and Pharmacophore modeling. Can. J. Chem. 2012, 90, 675–692.
  • Rhee, S-W., Iyer, R. P., Coughlin, J., Padmanabhan, S., Malerich, J. P., Tanga, M. J. Synthesis of a 35S-labeled dinucleoside phosphorothioate prodrug, an orally bioavailable anti-HBV agent. J. of Radiolabeled Compounds, 2012
  • Pissurlenkar, R.R.S., Khedkar, V. M., Iyer, R. P., Coutinho, E. Ensemble QSAR: A QSAR method based on conformational ensembles and metric descriptors. J. Comput. Chem. 2011, 32: 2204–2218.

Product Pipeline

Clinical Trials

See Details